Results 111 to 120 of about 9,401 (220)
Acta Médica Costarricense, 2010 Objetivo: Evaluar y caracterizar el abordaje farmacoterapéutico antiemético en el periodo postoperatorio en pacientes adultos sometidos a cirugía en el Hospital Clínica Bíblica (hospital privado en Costa Rica).
Natalia Apuy-Roldán +3 more
doaj
British Journal of Clinical Pharmacology, EarlyView.Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan +11 more
wiley +1 more source
Evaluating a virtual paediatric adverse drug reaction clinic
British Journal of Clinical Pharmacology, EarlyView.Aims Adverse drug reactions (ADRs) are a common problem in paediatric health care. There is limited access to expertise in the evaluation and management of potential ADRs in children, limiting access to these services and creating delays in assessment and management.
Emily Hauck +2 more
wiley +1 more source
Náuseas y vómitos postoperatorios con morfina liofilizada epidural. Su relacióncon algunasvariables
, 2011 Introduction and Objectives: Postoperative complications associated with epidural use of opioids limit its wider use as an analgesic method. The purpose of this research was to describe the behavior of postoperative nausea and vomiting with the ...
Marrero Font, Ilida +6 more
core
British Journal of Clinical Pharmacology, EarlyView.Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton +8 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus +4 more
wiley +1 more source
Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors
British Journal of Clinical Pharmacology, EarlyView.Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem +5 more
wiley +1 more source
Development of a nalmefene formulation suitable for a community‐use auto‐injector
British Journal of Clinical Pharmacology, EarlyView.Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano +6 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili +6 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar +3 more
wiley +1 more source